**Title of review**

Capsule endoscopy for the diagnosis and follow-up of Crohn’s disease: a comprehensive review of current status

**Running title**

*Jensen MD et al.* Capsule endoscopy in Crohn’s disease

**Authors**

1. Michael Dam Jensen, MD, PhD *(corresponding author)*

Department of Internal Medicine, Section of Gastroenterology

Lillebaelt Hospital Vejle

Kabbeltoft 25

7100 Vejle

Denmark

[michael.dam.jensen@rsyd.dk](mailto:Bjorn.Rasmussen@rsyd.dk)

Telephone: +45 7940 6345

Fax number: +45 7940 6887 (att.: Michael Dam Jensen)

1. Jacob Broder Brodersen, MD, Department of Internal Medicine, Section of Gastroenterology, Hospital of Southwest Jutland, Esbjerg, Denmark
2. Jens Kjeldsen, Professor, PhD, Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark

**Word count** (excluding title page, abstract, acknowledgements, references, figures and tables)

**References:** 89

**Figures:** 2

**Tables:** 4

**Conflicts of interest**

There are no conflicts of interest for any author. The authors alone are responsible for the content and writing of the paper without funding from private companies.

**Author contribution**

Jensen MD, Brodersen JB and Kjeldsen J designed the research; Jensen MD performed the data collection and data analysis; Jensen MD drafted the article; Brodersen JB and Kjeldsen J critically revised the article; Jensen MD, Brodersen JB and Kjeldsen J approved the final version.

**Abstract** (222 words)

Capsule endoscopy (CE) has revolutionized the diagnosis and monitoring of small bowel Crohn’s disease (CD). The procedure is patient friendly and noninvasive and compared to cross sectional imaging, CE allows a direct and detailed evaluation of the entire small bowel mucosa with a high sensitivity for the earliest lesions of CD. Today, CE is the leading modality for visualizing the small bowel in suspected CD, and validated activity indices are available for the follow-up of patients with established CD. CE of the entire gastrointestinal tract (panenteric capsule endoscopy) was recently introduced as a new diagnostic approach in patients examined for CD, and preliminary results are promising. There are important limitations, however, of which capsule retention is the main concern. Furthermore, a diagnostic criterion for CD has never been validated, and lesions detected at CE are not specific for CD. Hence, concern has been raised about a low specificity compared to other diagnostic modalities. Important questions about the optimal bowel preparation, selection of patients for CE and the optimal reading protocol remains to be clarified. The aim of this review is to evaluate the performance of CE for diagnosing CD and assess disease activity in known CD, compare the diagnostic accuracy of CE to cross sectional imaging, discuss limitations, and define the place of CE in the diagnostic algorithm in suspected or known CD.

**Key words (MeSH terms)**

Crohn Disease; Capsule Endoscopy; Diagnosis

**Introduction**

Before the era of capsule endoscopy (CE), the small bowel was considered inaccessible and difficult to examine. Endoscopic evaluation of the small bowel was limited to the most distal or proximal part with ileocolonoscopy and push enteroscopy, respectively or in selected cases intraoperative enteroscopy; all of which are invasive procedures requiring conscious sedation or general anesthesia [[1](#_ENREF_1)]. Although radiological procedures such as MR enterography and ultrasound have improved, they mainly visualize the transmural gut inflammation with limited sensitivity for superficial lesions [[2](#_ENREF_2), [3](#_ENREF_3)]. Since its FDA approval in 2001, CE has revolutionized small bowel imaging, and important knowledge about its clinical use has been gained. Main indications for CE are obscure gastrointestinal bleeding, suspected Crohn’s disease (CD), assessment of disease activity, mucosal healing and disease location in known CD, and discrimination between CD and ulcerative colitis / IBD unclassified [[4-6](#_ENREF_4)]. Other indications may include celiac disease, small bowel tumors, NSAID enteropathy, or polyposis syndromes. CE is a patient friendly and noninvasive procedure and compared to cross sectional imaging, CE allows a direct and detailed evaluation of the entire small bowel mucosa with detection of the earliest lesions of CD [[7](#_ENREF_7)]. However, there are important limitations of which capsule retention is the main concern (Table 1) [[5](#_ENREF_5), [8](#_ENREF_8), [9](#_ENREF_9)].

The aim of this review is to evaluate the performance of CE for diagnosing CD and assess disease activity in known CD, compare the diagnostic accuracy of CE to cross sectional imaging, discuss limitations, and define the place of CE in the diagnostic algorithm in suspected or known CD.

**Materials and methods**

An extensive English language literature search was conducted using PubMed to identify peer-reviewed original and review articles using the keywords ‘capsule endoscopy’, ‘suspected or known Crohn’s disease, ‘bowel cleansing’, ‘activity index’, ‘mucosal healing’, ‘C-reactive protein’, ‘fecal calprotectin’, ‘ileocolonoscopy’, ‘magnetic resonance imaging’, ‘computed tomography’, ‘ultrasound’, ‘postsurgical recurrence’, ‘capsule retention’, ‘quick view’, ‘Pillcam colon’, and ’panenteric capsule endoscopy’. The references of selected studies were manually searched to identify additional relevant studies. Systematic reviews and meta-analyses of randomized controlled trials were considered the highest level of evidence ([www.cebm.net](http://www.cebm.net)). Studies of diagnostic accuracy were reviewed in accordance with the QUADAS tool for quality assessment of diagnostic accuracy studies [[10](#_ENREF_10)].

**Capsule endoscopy systems**

There are currently five CE systems available for visualizing the small bowel: Pillcam SB3 (Medtronic, Dublin, Ireland), EndoCapsule EC-S10 (Olympus, Tokyo, Japan), MiroCam MC-1000W (Intromedic, Soul, South Korea), OMOM (Jinshan Science and Technology, Chongqing, China) and CapsoCam SV3 (CapsoVision, Saratoga, USA) [[11](#_ENREF_11)]. Furthermore, the Pillcam COLON2 (Medtronic, Dublin, Ireland) visualizes the small bowel, although it was designed for diagnosing the colon. Specifications provided by the manufacturers are shown in Table 2. Although CE systems are based on comparable technologies, important differences exist, e.g. the number of cameras, frame rate, angle of view, viewing direction, image resolution, and battery life. Theoretically, these differences could influence the diagnostic sensitivity for CD and the rate of complete small bowel examinations. However, studies comparing different CE systems head-to-head in patients with suspected or known CD are currently not available. In CD, the majority of studies have been performed with the Pillcam SB1 and SB2 as this CE system has dominated the world market for years. In patients with obscure gastrointestinal bleeding, studies comparing Pillcam SB1 with EndoCapsule [[12](#_ENREF_12), [13](#_ENREF_13)], Pillcam SB2 with MiroCam [[14](#_ENREF_14), [15](#_ENREF_15)], Pillcam SB2 with CapsoCam [[16](#_ENREF_16)], and EndoCapsule with MiroCam [[17](#_ENREF_17)] found no significant differences in diagnostic yields.

**Small bowel cleansing**

Numerous studies have examined the effect of bowel cleansing regimens on mucosal visualization, diagnostic yield and completion rates, and results have been included in several systematic reviews and meta-analyses [[18-21](#_ENREF_18)]. Original studies are heterogeneous in terms of included patients and scales used for determining the visualization quality. Results of individual studies are conflicting and meta-analyses have applied different inclusion criteria with varying recommendations. . In a meta-analysis of prospective randomized studies including 291 patients who had polyethylene glycol (PEG) administered before CE and 232 controls, the small bowel visibility was significantly better with PEG (odds ratio (OR) 3.11; 95% confidence interval (CI) 1.96-4.94), whereas no significant difference could be demonstrated between sodium phosphate treated patients and those on fasting only [[21](#_ENREF_21)]. Overall, bowel cleansing increased the diagnostic yield compared to fasting alone (OR 1.88; 95% CI 1.24-2.84). Simethicone improves the mucosal visualization but the effect on diagnostic yield remains to be established [[22](#_ENREF_22)]. Prokinetics do not seem to affect the small bowel CE completion rate [[20](#_ENREF_20)]. Hence, the current evidence suggests a bowel cleansing regimen containing PEG and Simethicone before small bowel CE. However, additional studies on this matter are warranted. It should be emphasized that studies mainly included patients with obscure gastrointestinal bleeding and only a minority of patients were examined for CD. Whether bowel cleansing improves the mucosal visualization, diagnostic sensitivity and disease severity assessment in patients with CD is unknown. On the contrary, bowel cleansing causes discomfort, and currently, there is no consensus on the use of bowel cleansing before CE in patients examined for CD.

**Suspected Crohn’s disease**

The cardinal lesions are mucosal ulcerations of varying severity (Figure 1); in its earliest stage as aphthous ulcerations defined by a mucosal break with surrounding erythema. Punched out, linear or irregular ulcers with cobblestone appearance and stenosis caused by inflammation or fibrosis are seen in more severe CD. Other findings such as erythema, edema and loss of villi without ulcerations are considered non-specific [[23](#_ENREF_23)]. It should be emphasized that ulcerations detected at CE are not specific for CD, and CE does not allow tissue sampling to support the diagnosis.

Lesions caused by NSAIDs are an important differential diagnosis because these drugs are frequently used in the general population. It is well established hat NSAIDs are associated with gastrointestinal ulcerations, bleeding and strictures, that lesions are visualized with CE and they can mimic CD [[24](#_ENREF_24), [25](#_ENREF_25)]. The precise number of weeks NSAIDs should be stopped prior to CE is unknown, but generally 4 weeks is recommended [[8](#_ENREF_8), [26](#_ENREF_26)].

A surprising finding by *Goldstein et al.* was that 11% of healthy volunteers who were *not* users of NSAIDs had mucosal breaks in the small bowel at a baseline CE [[25](#_ENREF_25)]. In the subsequent clinical study, 7% of patients with a normal baseline CE developed 1-3 mucosal breaks after placebo treatment. This raises an important question about the diagnostic criterion and minimum threshold for diagnosing CD in patients examined with CE. At this point, no such criterion has been validated [[23](#_ENREF_23), [26](#_ENREF_26)]. As suggested by *Mow et al.* the most frequently used diagnostic criterion for CD with CE is the presence of > 3 ulcerations in patients not using NSAIDs [[27](#_ENREF_27)].

Numerous studies have examined the clinical application of CE in patients with suspected or known CD. In the meta-analysis by *Dionisio et al.*, the diagnostic yield of CE in patients with suspected CD was superior to that of small bowel radiography (52% vs. 16%, *P* < 0.0001, n = 155), CT enterography (68% vs. 21%, *P* < 0.0001, n = 53) and ileocolonoscopy (47% vs. 25%, *P* = 0.009, n = 59) [[28](#_ENREF_28)]. Compared to MR enterography, CE had a higher diagnostic yield but the difference did not reach statistical significance (55% vs. 45%, *P* = 0.43, n = 31). These results suggest that CE is the best modality for diagnosing small bowel CD. However, the lack of a gold standard comparison may lead to false conclusions because false positive lesions count as true lesions, and this tends to favor the most sensitive modality. Although the majority of studies have used multiple ulcerations as diagnostic criterion for CD, the diagnostic threshold differs between studies and some studies included non-specific lesions or the diagnostic criterion was not described [[29-33](#_ENREF_29)]. In a 4-way comparison of CE, CT-enterography, small bowel follow-through and ileocolonoscopy, the specificity of CE (53%) was significantly lower compared to the other tests supporting a high diagnostic yield because of false positive lesions [[30](#_ENREF_30)]. A downside of this study, however, was that no criterion for diagnosing CD with CE was applied. A consensus gold standard based on the clinical presentation and results of all four modalities was used but individual cases of disagreement were not discussed. Other prospective studies have compared CE with varying gold standards showing a high sensitivity and specificity of CE for diagnosing CD (Table 3) [[7](#_ENREF_7), [29](#_ENREF_29), [34](#_ENREF_34)].

**Selecting patients for capsule endoscopy**

To increase the diagnostic yield and avoid unnecessary diagnostic procedures, related expenses and patient discomfort, careful selection of patients for CE is of great importance. Relevant decision tools in this regard are biomarkers, fecal markers and the result of a preceding ileocolonoscopy.

A prospective study evaluated 72 patients with chronic abdominal pain with or without diarrhea and no explanation after ileocolonoscopy and upper endoscopy [[35](#_ENREF_35)]. The diagnostic yield of CE was 67% and 21% in patients with or without increased markers of inflammation, respectively. A diagnosis of CD was obtained in 25% of patients – primarily in patients with abdominal pain, diarrhea and elevated markers of inflammation. Similarly, in a study by *De Bona et al.*, CE detected lesions consistent with CD in 46% of patients with suspected CD and elevated biomarkers of inflammation compared to 8% in patients with normal biomarkers [[36](#_ENREF_36)]. An elevated C-reactive protein (CRP) has been shown to have a sensitivity, specificity and positive predictive value of 73%, 69% and 89% for diagnosing CD in the small bowel [[37](#_ENREF_37)]. However, other studies have provided less favorable results. In a retrospective study of 189 patients with known small bowel CD, an elevated CRP was poorly associated with significant inflammatory lesions detected at CE consistent with the body of evidence in general showing a suboptimal sensitivity of CRP for CD [[38-40](#_ENREF_38)]. Hence, in patients with gastrointestinal symptoms suggestive of CD but a normal ileocolonoscopy, elevated markers of inflammation seems to be associated with an increased diagnostic yield of CE and in this situation, CE should be considered. However, the sensitivity of CRP is inadequate and a normal value does not exclude small bowel CD.

Fecal calprotectin (fCal) is a highly sensitive marker of gastrointestinal inflammation although it is not specific for inflammatory bowel disease. A normal value has a high negative predictive value and virtually excludes ileocolonic CD [[41](#_ENREF_41), [42](#_ENREF_42)]. The utility of fCal for small bowel CD, however, has been debated. Some studies have reported lower levels of fCal in small bowel CD compared to CD involving the colon [[43](#_ENREF_43), [44](#_ENREF_44)], whereas other studies have found equal levels and a high sensitivity of fCal for small bowel CD [[45](#_ENREF_45)]. Similarly, data on the ability of fCal to predict findings at CE have been conflicting. In a retrospective study by *Koulaouzidis et al.*, a fCal > 100 mg/kg was a good predictor of small bowel CD detected with CE in patients with suspected CD but a negative bi-directional endoscopy, and a fCal < 100 mg/kg excluded small bowel CD [[46](#_ENREF_46)]. In subsequent studies, however fCal was an inadequate biomarker for inflammatory lesions in the small bowel with a sensitivity of 59-70% and a specificity of 44-71% [[38](#_ENREF_38), [47](#_ENREF_47)]. In a recent meta-analysis including 463 patients with a clinical relevant indication for performing CE, fCal > 50 mg/kg had a sensitivity and specificity of 83% and 53% for detection of small bowel CD [[48](#_ENREF_48)].

Few studies have examined the benefit of performing CE after ileocolonoscopy. In a study comparing CE with ileocolonoscopy in patients with suspected small bowel CD, diagnostic yields for the terminal ileum and cecum were comparable [[49](#_ENREF_49)]. A total of 25 patients were diagnosed with small bowel CD of which 11 were solely diagnosed based on the result of CE (lesions isolated in the proximal small bowel in 3). This study suggests that ileocolonoscopy and CE are complementary modalities for diagnosing CD in the terminal ileum, that ileocolonoscopy should be the primary diagnostic modality, and that CE is of benefit in patients with a negative ileocolonoscopy. On the contrary, in a study of 93 patients with suspected CD, limited diagnostic information was gained with CE in patients with CD in the colon and a normal terminal ileum or patients with non-complicated CD in the terminal ileum detected at ileocolonoscopy [[50](#_ENREF_50)].

**Diagnostic algorithm in suspected Crohn’s disease**

Ileocolonoscopy is the accepted gold standard for diagnosing CD located the colon and terminal ileum and currently recommended as the initial diagnostic modality in suspected CD [[51](#_ENREF_51)]. In the majority of patients, CD is located within the reach of the colonoscope whereas CD isolated in the upper small bowel without involvement of the colon or terminal ileum is uncommon [[52](#_ENREF_52)]. At present time, international guidelines recommend small bowel imaging in all patients with a clinical suspicion of CD irrespective of the findings at ileocolonoscopy (evidence level 5, recommendation grad D), and CE should be the first line investigation in patients without obstructive symptoms (Figure 2A) [[8](#_ENREF_8), [26](#_ENREF_26), [51](#_ENREF_51)]. In patients with obstructive symptoms or known stenosis, cross sectional imaging such as MR enterography or CT enterography is preferred. However, additional studies determining the benefit and clinical impact of performing CE in adult patients with suspected CD after ileocolonoscopy are warranted. Future guidelines should also consider non-invasive markers such as fCal as a tool for selecting patients for ileocolonoscopy. An alternative algorithm based on a single prospective study of fCal, ileocolonoscopy, CE and cross sectional imaging in suspected CD has previously been published by our group [[50](#_ENREF_50)]: Patients with an elevated fCal should undergo colonoscopy including a persistent attempt to intubate the terminal ileum. In patients with a normal ileocolonoscopy or non-complicated CD in the colon and/or terminal ileum, small bowel imaging provides little extra information compared to ileoscopy alone. Small bowel imaging is primarily indicated if ileoscopy is not achieved and capsule endoscopy is the preferred first line imaging technique. MRE and CTE are complimentary modalities preferably used in patients with stenosis detected at ileocolonoscopy or suspicion of extra-intestinal disease complications. Additional studies are required to validate this diagnostic approach.

**Known Crohn’s disease**

In the majority of patients, the phenotype of CD changes over time from mainly inflammatory lesions at the time of diagnosis to stricturing or penetrating disease [[53](#_ENREF_53)]. Correspondingly, a large number of patients require surgery within the first 10 years of diagnosis [[53](#_ENREF_53), [54](#_ENREF_54)], and the utility of CE is hampered by the risk of capsule retention. In a comprehensive literature review, capsule retention occurred in 2.6% of patients examined for suspected or known CD [[55](#_ENREF_55)], and retention rates of 4-13% have been reported in patients with symptomatic CD [[56](#_ENREF_56)].

In the meta-analysis by *Dionisio et al.*, the diagnostic yield of CE in patients with known CD was superior to that of small bowel radiography (71% vs. 36%, *P* < 0.00001, n = 224) and CT enterography (71% vs. 39%, *P* < 0.0001, n = 66) [[28](#_ENREF_28)]. There was a trend towards a higher yield compared to ileocolonoscopy (70% vs. 57%, *P* = 0.07, n = 158), whereas MR enterography had an equally high diagnostic yield (*P* = 0.65). It should be emphasized, however, that original studies excluded patients with a radiological suspicion of small bowel stenosis. Therefore, CE is superior to cross sectional imaging and ileocolonoscopy in a subgroup of patients with non-stricturing CD which tends to favor the most sensitive modality for mucosal inflammation, i.e. endoscopy over cross sectional imaging.

There is a lack of prospective studies directly comparing the feasibility, sensitivity and specificity of CE with that of cross sectional imaging in patients with known CD. In retrospective studies on this group of patients, CE was safe and added significant diagnostic information in a large number of patients with a subsequent impact on clinical decision [[38](#_ENREF_38), [57](#_ENREF_57)]. Compared to cross sectional imaging, CE detects significant more lesions in the proximal small bowel, primarily in the form of mild lesions [[7](#_ENREF_7), [58](#_ENREF_58)]. The clinical significance of this diagnostic information has previously been debated [[26](#_ENREF_26)]. However, a recent retrospective study of 108 patients with known CD found jejunal lesions in more than half of the patients, and the presence of proximal lesions was an independent risk factor of future clinical relapse (adjusted hazard ratio of 1.99; 95% CI, 1.10–3.61; *P* = 0.02) [[59](#_ENREF_59)]. Hence, the increased sensitivity of CE for proximal small bowel lesions compared to cross sectional imaging seems to have prognostic importance and an impact on clinical decision. Furthermore, the patient experienced discomfort is significantly lower with CE compared to cross sectional imaging, and 78% of patients would prefer this modality as a future examination [[7](#_ENREF_7), [60](#_ENREF_60)].

**Diagnostic algorithm in known Crohn’s disease**

In patients with symptomatic CD, current guidelines recommend dedicated small imaging irrespective of the findings at ileocolonoscopy because detection of lesions may have prognostic and therapeutic implications (Figure 2B) [[8](#_ENREF_8), [51](#_ENREF_51)]. In this group of patients, the prevalence of disease complications is high, and cross sectional imaging is the preferred modality for diagnosing inflammatory lesions and strictures beyond the reach of the colonoscope as well as fistulas and abscesses. CE should be reserved as a second line modality in patients with unexplained symptoms after ileocolonoscopy and cross sectional imaging if symptoms require further evaluation, and findings are expected to alter medical treatment. CE should be preceded by either cross sectional imaging or examination with a patency capsule to avoid capsule retention [[8](#_ENREF_8), [26](#_ENREF_26)].

**Assessment of disease activity and mucosal healing**

There are currently two validated indexes available for assessing the disease location and severity of small bowel CD with CE (Table 4). The *Lewis score* evaluates three small bowel segments for the parameters villous appearance, ulcers and stenosis [[61](#_ENREF_61)].The *Capsule Endoscopy Crohn’s Disease Activity Index* (CECDAI) evaluates the proximal and distal small bowel for the parameters inflammatory lesions, disease extension and stenosis [[62](#_ENREF_62)]. A software application for calculation of the Lewis score has been incorporated into the RAPID Reader platform for Pillcam SB. The following cutoffs have been proposed: < 135 is consistent with a normal small bowel or clinically insignificant inflammation, 135-790 is mild disease activity, and > 790 denotes moderate to severe disease [[61](#_ENREF_61)]. The CECDAI is simpler to calculate, but cut-offs for endoscopic remission and different disease severities have not been properly established. However, there is a good correlation between the two indexes (r = 0.63, *P* < 0.0001), and in a retrospective and unblinded single reader analysis, CECDAI levels of 3.8 and 5.8 corresponded to a Lewis score of 135 and 790, respectively [[40](#_ENREF_40), [63](#_ENREF_63)].

Although the Lewis score and CECDAI are able to quantify the severity of mucosal inflammation, it should be emphasized that they cannot be applied as diagnostic tools in general because parameters included in the scores are not disease specific. In a retrospective study, however, of 95 patients with suspected CD, a normal ileocolonoscopy and follow-up as gold standard, a Lewis score ≥ 135 had a sensitivity and specificity of 89.5% and 78.9%, respectively, for the diagnosis of CD [[64](#_ENREF_64)]. A Lewis score < 135 excluded CD with a negative predictive value of 92%. Hence, in patients with suspected CD, a normal Lewis score virtually excludes the diagnosis. In patients with findings consistent with CD, i.e. multiple ulcerations, both the Lewis score and CECDAI may be applied to quantify the disease severity and location.

A few studies have examined the applicability of CE as a tool for monitoring treatment response and mucosal healing in small bowel CD. Currently, however, there is no validated criterion for mucosal healing with CE [[8](#_ENREF_8)]. Equivalent to ileocolonic CD, achieving clinical remission is only paralleled by mucosal healing in a minority of patients with small bowel CD. Hence, CE may serve as an objective tool for monitoring the treatment response and mucosal healing [[40](#_ENREF_40), [65](#_ENREF_65), [66](#_ENREF_66)]. The clinical benefit of using CE as a disease monitoring tool with treatment escalation in patients who have not achieved mucosal healing needs to be shown. No studies have compared CE to cross sectional imaging in these matters.

**Postsurgical recurrence**

One year after surgical resection of the terminal ileum because of CD, inflammatory lesions can be detected endoscopically in 73-93% of patients, although clinical recurrence only occurs in 20-37% at this point in time [[67](#_ENREF_67), [68](#_ENREF_68)]. Detection of postsurgical recurrence may have important therapeutic implications. *Boureille et al.* compared CE to ileocolonoscopy for detection of postsurgical recurrence in 32 patients a median of 6 months after an ileocolonic resection [[69](#_ENREF_69)]. With a composite gold standard including both the results of ileocolonoscopy and CE analyzed by two observers, the sensitivity of CE was inferior to that of ileocolonoscopy for detection of disease recurrence in the neoterminal ileum (62-76% vs. 90%, respectively). However, CE detected inflammatory lesions outside the reach of the colonoscope in two thirds of patients. The severity of lesions detected with ileocolonoscopy and CE correlated significantly (*r* = 0.54-0.64, *P* < 0.05). In a similar study by *Pons Beltran et al.* both endoscopic procedures were performed in 22 patients 6-12 months after ileocolonic resection [[70](#_ENREF_70)]. Ileocolonoscopy and CE detected postsurgical recurrence in the neoterminal ileum in 6 and 15 patients, respectively. Lesions beyond the reach of the colonoscope were detected in 13 patients with CE including 3 patients without involvement of the neoterminal ileum. All patients preferred CE over ileocolonoscopy.

Hence, data regarding the sensitivity of CE for detection of postsurgical recurrence in the neoterminal ileum are conflicting, and the applicability of CE in this situation remains to be clarified. Currently, ileocolonoscopy is considered gold standard, and the *Rutgeerts’ score* is recommended for determining the disease severity [[26](#_ENREF_26)]. Lesions of increasing severity found at ileocolonoscopy is a strong predictor for clinical recurrence, and current ECCO guidelines recommend ileocolonoscopy 6–12 months after surgery where treatment decisions may be affected [[26](#_ENREF_26)]. In patients without obstructive symptoms who are unwilling to undergo ileocolonoscopy, CE seems to be a safe and patient friendly alternative with a high diagnostic yield for CD recurrence in both the proximal and distal small bowel.

**Small bowel patency**

If a small bowel stenosis is not firmly excluded, the Pillcam patency capsule (Medtronic, Dublin, Ireland) can be used to confirm small bowel patency before performing CE. The patency capsule is a dissolvable capsule with the same size as the Pillcam SB3 capsule (26 x 11 mm). It is composed of a lactose body mixed with barium and a radio frequency identification (RFID) tag. In each end, the patency capsule has a timer plug designed to erode after 30 hours resulting in disintegration of the capsule, and it has been stated, that all patency capsules are dissolved within 72 hours [[71](#_ENREF_71)]. Capsule endoscopy is considered safe if the patency capsule is excreted before 30 hours, an intact capsule is excreted after 30 hours, or passage to the colon of an intact patency capsule has been radiologically confirmed.

*Herrerias et al.* examined the Pillcam patency capsule in 106 patients with radiographic evidence of a small bowel stricture [[72](#_ENREF_72)]. Small bowel patency was confirmed in 59, and none of these patients experienced capsule retention at a subsequent capsule endoscopy. No severe adverse events could be attributed to the patency capsule. Furthermore, *Yadav et al.* concluded that the Pillcam patency capsule and radiological examination were equally reliable for excluding small bowel obstruction or strictures [[73](#_ENREF_73)]. Hence, available studies suggest that the Pillcam patency capsule is equal to radiology and a safe method for testing small bowel patency before capsule endoscopy, even in patients with a radiologically verified stenosis. However, symptomatic and potentially severe capsule retention with the Pillcam patency capsule has been reported [[74](#_ENREF_74), [75](#_ENREF_75)]. In a recent multicenter case series of 1615 patients examined with the Pillcam patency capsule, 20 (1.2%) symptomatic cases of capsule retention were identified [[76](#_ENREF_76)]. One patient required surgery; all other patients with a retained patency capsule in the small bowel resolved spontaneously or after corticosteroid therapy. Hence, symptomatic patency capsule retention is uncommon and the prognosis is good.

**Reading protocols**

A significant limitation with CE is the time consumption required for video analysis. In previous series, reading times above 40-50 minutes were reported [[77](#_ENREF_77)], and ways to reduce reading times without affecting the diagnostic accuracy would be helpful in clinical practice. Particularly in CD, increasing the viewing speed may be feasible because this disease is characterized by multiple lesions that are most often widespread in the small bowel.

Given Imaging’s RAPID Reader enables alterations of the viewing mode from single to dual or quad view, and the frame rate can be adjusted from 5 to 40 frames per second (fr/s). *Gunther et al.* compared single view at a speed of 10 fr/s with quad view at 20 fr/s [[78](#_ENREF_78)]. The mean reading time was reduced from 22 minutes to 12 minutes, and detection rates of angioectasias, erosions, ulcers, and polyps were significantly lower with quad view. However, in patients with suspected or known CD, overlooked lesions did not change the result of the examination. Recently, *Nakamura et al.* compared single view, dual view and quad view at different frame rates using a small bowel video sequence with 60 pathological images of small bowel angioectasias [[79](#_ENREF_79)]. Increasing the frame rate from 10 to 15, 25 and 40 fr/s resulted in a 33, 60, and 72% reduction in playing time, respectively but at the expense of fewer lesions detected. Altering the viewing mode had no effect on the reading time for any given frame rate but the detection rate was significantly higher with dual and quad view compared to single view. The authors conclude that the optimal combination for a high detection rate is 10 fr/s using dual or quad view.

Another way to decrease reading times is by reducing the number of images presented to the capsule endoscopist. The quick view function provided by Given Imaging’s RAPID Reader filters the number of images shown. With a sampling rate of 10% (default setting), 10% of images from the original videos is shown. Images are filtered according to a specific algorithm developed by the manufacturer, and sampling rates between 2% and 80% can be chosen. *Shiotani et al.* examined how different sampling rates affect detection rates of quick view CE [[80](#_ENREF_80)]. A variety of preselected lesions were included in the study. With a 5, 15, 25 and 35% sampling rate, 61, 74, 93 and 98% of lesions were detected. With a 25% sampling rate, only 7% of lesions were missed, and the reading time was reduced by approximately 50%. This setting was considered a proper trade-off between reading times and detection rates. *Koulaouzidis et al.* studied 81 patients with suspected or known CD [[81](#_ENREF_81)]. A total of 155 and 71 ulcerations were detected with CE and quick view CE, respectively with a 35% sampling rate corresponding to a miss rate of 54%. In patients with suspected or known CD, quick view CE was false negative (i.e. no or non-specific lesions or < 3 ulcerations) in 1 (7%) and 8 (10%) patients, respectively. In a study by our group including 40 patients with suspected CD, standard view CE visualized 171 small bowel ulcerations compared to 102 lesions detected with quick view CE (miss rate 40%, *P* = 0.02) [[82](#_ENREF_82)]. However, with ileocolonoscopy and standard view CE as gold standard, quick view CE diagnosed 15 of 16 patients with small bowel CD corresponding to a 94% sensitivity, and overall, 39 out of 40 patients were classified correct (diagnostic accuracy 98%). Reading times varied from 5 to 18 min (median 10).

Hence, the available software for analyzing CEs allows for faster reading times; either by increasing the frame rate with or without altering the viewing mode or using the quick view function. However, reduced reading times comes at a cost; increasing the speed results in lower detection rates. Data on patients with suspected or known CD are scarce, but available data suggest that despite fewer lesions detected, the overall sensitivity for CD is acceptable, and the quick view function may serve as a method for screening for CD lesion; especially in patients with suspected CD. Additional studies in patients with suspected or known CD are warranted and currently, a generally accepted reading protocol has not been established [[83](#_ENREF_83)].

**Panenteric capsule endoscopy**

Using CE for evaluating both the small bowel and colon in a single non-invasive examination is an attractive diagnostic approach. Pillcam colon capsule endoscopy (PCCE) was introduced in 2006 and soon a panenteric capsule endoscope will be available; i.e. the small bowel colon (SBC) capsule (Medtronic, Dublin, Ireland) The SBC capsule is similar to the Pillcam COLON2 in all its hardware components, but it is designed to provide complete coverage of the small bowel and colon [[84](#_ENREF_84)]. Until now, few studies have evaluated this modality for diagnosing CD in the colon and small intestine.

Performing CE of the colon requires optimal cleansing, and the *European Society of Gastrointestinal Endoscopy* currently recommends a regimen consisting of 4 liters of polyethylene glycol (PEG) in two divided doses and sodium phosphate (Phosphoral) as booster [[85](#_ENREF_85)]. In a prospective study of patients with known CD, the patient reported discomfort was significantly lower with PCCE compared to ileocolonoscopy [[86](#_ENREF_86)]. PCCE had a sensitivity of 86% for detection for ulcerations in the colon and terminal ileum, and lesions outside the reach of the colonoscope was detected in 15% of patients. There was a moderate correlation between PCCE and ileocolonoscopy for assessing of disease severity. In a prospective study of 38 pediatric patients with CD, PCCE was compared to magnetic resonance enterography (MRE) and small intestine contrast ultrasonography (SICUS) [[87](#_ENREF_87)]. The sensitivity of PCCE to detect colonic inflammation was 89%, and the specificity was 100%. In the small bowel, PCCE had a 90% sensitivity and a 94% specificity. The diagnostic accuracies of MRE and SICUS were slightly lower compared to PCCE although differences were not statistically significant. The tolerability of PCCE was superior compared to ileocolonoscopy, and the interobserver agreement was excellent (κ = 0.91).

In a recent study, *Leighton et al.* compared the diagnostic yield of the SBC capsule with ileocolonoscopy in 66 patients with clinically active CD [[84](#_ENREF_84)]. The per-subject diagnostic yield for CD lesions was 83.3% for the SBC capsule and 69.7% for ileocolonoscopy (incremental yield 13.6% (95% CI, 2.6-24.7%). A greater percentage of active lesions was detected in each evaluated segment by the SBC capsule as compared with ileocolonoscopy, and the overall per-segment diagnostic yield was 40.6% for the SBC capsule and 32.7% for ileocolonoscopy (incremental yield 7.9%; 95% CI, 3.3-12.4%).

Hence, preliminary data suggest that CE is a feasible diagnostic modality in patients examined for non-obstructive CD. Additional studies evaluating panenteric capsule endoscopy for diagnosing CD and comparison with ileocolonoscopy and radiological modalities in terms of patient experienced discomfort, complications and interobserver agreement are warranted.

**Conclusion**

CE has revolutionized the diagnosis and monitoring of small bowel CD. The procedure is patient friendly and noninvasive and compared to cross sectional imaging, CE allows a direct and detailed evaluation of the entire small bowel mucosa with a high sensitivity for the earliest lesions of CD. Today, CE is the leading modality for visualizing the small bowel in suspected CD, and validated activity indices are available for the follow-up of patients with established CD. CE of the entire gastrointestinal tract was recently introduced as a new diagnostic approach, and preliminary data show a high sensitivity, specificity, interobserver agreement and tolerability compared to ileocolonoscopy. There are important limitations, however, of which capsule retention is the main concern. Furthermore, a diagnostic criterion for CD has never been validated, and lesions detected at CE are not specific for CD. Hence, concern has been raised about a low specificity compared to other diagnostic modalities. Future studies should address important questions about the optimal bowel preparation for small bowel CE and panenteric capsule endoscopy, selection of patients for CE in suspected or known CD, the optimal reading protocol and the diagnostic performance of panenteric capsule endoscopy compared to cross sectional imaging.

**Acknowledgements**

None

**References**

1. Committee AT, Chauhan SS, Manfredi MA, et al. Enteroscopy. Gastrointest Endosc. 2015;82:975-990.

2. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7:556-585.

3. Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34:125-145.

4. Committee AT, Wang A, Banerjee S, et al. Wireless capsule endoscopy. Gastrointest Endosc. 2013;78:805-815.

5. Koulaouzidis A, Rondonotti E, Karargyris A. Small-bowel capsule endoscopy: a ten-point contemporary review. World J Gastroenterol. 2013;19:3726-3746.

6. Greener T, Klang E, Yablecovitch D, et al. The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohns Colitis. 2016;10:525-531.

7. Jensen MD, Nathan T, Rafaelsen SR, et al. Diagnostic accuracy of capsule endoscopy for small bowel Crohn's disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol. 2011;9:124-129.

8. Pennazio M, Spada C, Eliakim R, et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2015;47:352-376.

9. Mitselos IV, Christodoulou DK, Katsanos KH, et al. Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease. World J Gastrointest Endosc. 2015;7:643-651.

10. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.

11. Keuchel M, Hagenmüller F, Tajiri H. Video Capsule Endoscopy. 1 ed: Springer-Verlag Berlin Heidelberg; 2014.

12. Cave DR, Fleischer DE, Leighton JA, et al. A multicenter randomized comparison of the Endocapsule and the Pillcam SB. Gastrointest Endosc. 2008;68:487-494.

13. Hartmann D, Eickhoff A, Damian U, et al. Diagnosis of small-bowel pathology using paired capsule endoscopy with two different devices: a randomized study. Endoscopy. 2007;39:1041-1045.

14. Pioche M, Gaudin JL, Filoche B, et al. Prospective, randomized comparison of two small-bowel capsule endoscopy systems in patients with obscure GI bleeding. Gastrointest Endosc. 2011;73:1181-1188.

15. Choi EH, Mergener K, Semrad C, et al. A multicenter, prospective, randomized comparison of a novel signal transmission capsule endoscope to an existing capsule endoscope. Gastrointest Endosc. 2013;78:325-332.

16. Pioche M, Vanbiervliet G, Jacob P, et al. Prospective randomized comparison between axial- and lateral-viewing capsule endoscopy systems in patients with obscure digestive bleeding. Endoscopy. 2014;46:479-484.

17. Dolak W, Kulnigg-Dabsch S, Evstatiev R, et al. A randomized head-to-head study of small-bowel imaging comparing MiroCam and EndoCapsule. Endoscopy. 2012;44:1012-1020.

18. Rokkas T, Papaxoinis K, Triantafyllou K, et al. Does purgative preparation influence the diagnostic yield of small bowel video capsule endoscopy?: A meta-analysis. Am J Gastroenterol. 2009;104:219-227.

19. Koulaouzidis A, Giannakou A, Yung DE, et al. Do prokinetics influence the completion rate in small-bowel capsule endoscopy? A systematic review and meta-analysis. Curr Med Res Opin. 2013;29:1171-1185.

20. Kotwal VS, Attar BM, Gupta S, et al. Should bowel preparation, antifoaming agents, or prokinetics be used before video capsule endoscopy? A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:137-145.

21. Belsey J, Crosta C, Epstein O, et al. Meta-analysis: efficacy of small bowel preparation for small bowel video capsule endoscopy. Curr Med Res Opin. 2012;28:1883-1890.

22. Wu L, Cao Y, Liao C, et al. Systematic review and meta-analysis of randomized controlled trials of Simethicone for gastrointestinal endoscopic visibility. Scand J Gastroenterol. 2011;46:227-235.

23. Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy. 2009;41:618-637.

24. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5:1040-1045.

25. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133-141.

26. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.

27. Mow WS, Lo SK, Targan SR, et al. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004;2:31-40.

28. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009;105:1240-1248.

29. Albert JG, Martiny F, Krummenerl A, et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut. 2005;54:1721-1727.

30. Solem CA, Loftus EV, Jr., Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68:255-266.

31. Golder SK, Schreyer AG, Endlicher E, et al. Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. Int J Colorectal Dis. 2006;21:97-104.

32. Eliakim R, Suissa A, Yassin K, et al. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease--final report. Dig Liver Dis. 2004;36:519-522.

33. Efthymiou A, Viazis N, Vlachogiannakos J, et al. Wireless capsule endoscopy versus enteroclysis in the diagnosis of small-bowel Crohn's disease. Eur J Gastroenterol Hepatol. 2009;21:866-871.

34. Dubcenco E, Jeejeebhoy KN, Petroniene R, et al. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn's disease: correlation with radiologic, endoscopic, and histologic findings. Gastrointest Endosc. 2005;62:538-544.

35. Katsinelos P, Fasoulas K, Beltsis A, et al. Diagnostic yield and clinical impact of wireless capsule endoscopy in patients with chronic abdominal pain with or without diarrhea: a Greek multicenter study. European journal of internal medicine. 2011;22:e63-66.

36. De Bona M, Bellumat A, Cian E, et al. Capsule endoscopy findings in patients with suspected Crohn's disease and biochemical markers of inflammation. Dig Liver Dis. 2006;38:331-335

37. Yang L, Ge ZZ, Gao YJ, et al. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease. J Gastroenterol Hepatol. 2013;28:829-833.

38. Kopylov U, Nemeth A, Koulaouzidis A, et al. Small bowel capsule endoscopy in the management of established Crohn's disease: clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm Bowel Dis. 2015;21:93-100.

39. Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015;110:802-819; quiz 820.

40. Kopylov U, Yablecovitch D, Lahat A, et al. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323.

41. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.

42. Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444-454.

43. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169.

44. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.

45. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol. 2011;46:694-700.

46. Koulaouzidis A, Douglas S, Rogers MA, et al. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol. 2011;46:561-566.

47. Sipponen T, Haapamaki J, Savilahti E, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47:778-784.

48. Kopylov U, Yung DE, Engel T, et al. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28:1137-1144.

49. Leighton JA, Gralnek IM, Cohen SA, et al. Capsule endoscopy is superior to small-bowel follow-through and equivalent to ileocolonoscopy in suspected Crohn's disease. Clin Gastroenterol Hepatol. 2014;12:609-615.

50. Jensen MD, Nathan T, Rafaelsen SR, et al. Ileoscopy reduces the need for small bowel imaging in suspected Crohn's disease. Dan Med J. 2012;59:A4491.

51. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.

52. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122.

53. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.

54. Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996-1006.

55. Liao Z, Gao R, Xu C, et al. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. Gastrointest Endosc. 2010;71:280-286.

56. Cheifetz AS, Kornbluth AA, Legnani P, et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol. 2006;101:2218-2222.

57. Kalla R, McAlindon ME, Drew K, et al. Clinical utility of capsule endoscopy in patients with Crohn's disease and inflammatory bowel disease unclassified. Eur J Gastroenterol Hepatol. 2013;25:706-713.

58. Voderholzer WA, Beinhoelzl J, Rogalla P, et al. Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut. 2005;54:369-373

59. Flamant M, Trang C, Maillard O, et al. The prevalence and outcome of jejunal lesions visualized by small bowel capsule endoscopy in Crohn's disease. Inflamm Bowel Dis. 2013;19:1390-1396.

60. Lahat A, Kopylov U, Amitai MM, et al. Magnetic resonance enterography or video capsule endoscopy - what do Crohn's disease patients prefer? Patient Prefer Adherence. 2016;10:1043-1050.

61. Gralnek IM, Defranchis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008;27:146-154.

62. Gal E, Geller A, Fraser G, et al. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci. 2008;53:1933-1937.

63. Koulaouzidis A, Douglas S, Plevris JN. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index. Dig Dis Sci. 2012;57:987-993.

64. Monteiro S, Boal Carvalho P, Dias de Castro F, et al. Capsule Endoscopy: Diagnostic Accuracy of Lewis Score in Patients with Suspected Crohn's Disease. Inflamm Bowel Dis. 2015;21:2241-2246.

65. Hall B, Holleran G, Chin JL, et al. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. J Crohns Colitis. 2014;8:1601-1609.

66. Efthymiou A, Viazis N, Mantzaris G, et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis. 2008;14:1542-1547.

67. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-963.

68. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331-335.

69. Bourreille A, Jarry M, D'Halluin PN, et al. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut. 2006;55:978-983.

70. Pons Beltran V, Nos P, Bastida G, et al. Evaluation of postsurgical recurrence in Crohn's disease: a new indication for capsule endoscopy? Gastrointest Endosc. 2007;66:533-540.

71. Lewis BS. Expanding role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol. 2008;14:4137-4141.

72. Herrerias JM, Leighton JA, Costamagna G, et al. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc. 2008;67:902-909.

73. Yadav A, Heigh RI, Hara AK, et al. Performance of the patency capsule compared with nonenteroclysis radiologic examinations in patients with known or suspected intestinal strictures. Gastrointest Endosc. 2011;74:834-839.

74. Nemeth A, Kopylov U, Koulaouzidis A, et al. Use of patency capsule in patients with established Crohn's disease. Endoscopy. 2016;48:373-379.

75. Rasmussen B, Nathan T, Jensen MD. Symptomatic Patency Capsule Retention in Suspected Crohn's Disease. J Crohns Colitis. 2016.

76. Kopylov U, Nemeth A, Cebrian A, et al. Symptomatic retention of the patency capsule: a multicenter real life case series. Endosc Int Open. 2016;4:E964-969.

77. Sidhu R, Sanders DS, Morris AJ, et al. Guidelines on small bowel enteroscopy and capsule endoscopy in adults. Gut. 2008;57:125-136.

78. Gunther U, Daum S, Zeitz M, et al. Capsule endoscopy: comparison of two different reading modes. Int J Colorect Dis. 2012;27:521-525

79. Nakamura M, Murino A, O'Rourke A, et al. A critical analysis of the effect of view mode and frame rate on reading time and lesion detection during capsule endoscopy. Dig Dis Sci. 2015;60:1743-1747.

80. Shiotani A, Honda K, Kawakami M, et al. Analysis of small-bowel capsule endoscopy reading by using Quickview mode: training assistants for reading may produce a high diagnostic yield and save time for physicians. J Clin Gastroenterol. 2012;46:e92-95.

81. Koulaouzidis A, Smirnidis A, Douglas S, et al. QuickView in small-bowel capsule endoscopy is useful in certain clinical settings, but QuickView with Blue Mode is of no additional benefit. Eur J Gastroenterol Hepatol. 2012;24:1099-1104.

82. Halling ML, Nathan T, Kjeldsen J, et al. High sensitivity of quick view capsule endoscopy for detection of small bowel Crohn's disease. J Gastroenterol Hepatol. 2014;29:992-996.

83. Koulaouzidis A, Toth E. Optimizing the interpretation of capsule endoscopic images: shortsighted or taking the long view? Dig Dis Sci. 2015;60:1519-1521.

84. Leighton JA, Helper DJ, Gralnek IM, et al. Comparing diagnostic yield of a novel pan-enteric video capsule endoscope with ileocolonoscopy in patients with active Crohn's disease: a feasibility study. Gastrointest Endosc. 2016.

85. Spada C, Hassan C, Galmiche JP, et al. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2012;44:527-536.

86. D'Haens G, Lowenberg M, Samaan MA, et al. Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease. Clin Gastroenterol Hepatol. 2015;13:1480-1486 e1483.

87. Oliva S, Cucchiara S, Civitelli F, et al. Colon capsule endoscopy compared with other modalities in the evaluation of pediatric Crohn's disease of the small bowel and colon. Gastrointest Endosc. 2016;83:975-983.

88. Song HJ, Shim KN. Current status and future perspectives of capsule endoscopy. Intest Res. 2016;14:21-29.

89. Tukey M, Pleskow D, Legnani P, et al. The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol. 2009;104:2734-2739.

**TABLES**

**Table 1** Advantages and limitations of small bowel capsule endoscopy in Crohn’s disease

|  |  |
| --- | --- |
| Advantages | Limitations |
| Non-invasive | Risk of capsule retention in stricturing CD |
| Patient friendly | Inability to take biopsies |
| Direct mucosal evaluation | Significant number of incomplete examinations\* |
| Significantly higher diagnostic yield for CD compared to other modalities | Analysis is time consuming |
| Better visualization of the proximal small bowel compared to other modalities | Longer procedure time compared to radiological modalities |

\* In a systematic review of 2,295 CE’s performed in suspected or known CD, a completion rate of 85%

was reported [[55](#_ENREF_55)]

**Table 2** Specifications of available capsule endoscopy systems for examining the small bowel. The Pillcam COLON2 was designed for studying the colon but it also visualizes the small bowel.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Medtronic | Medtronic | Olympus | Intromedic | Jinshan Science and Technology | CapsoVision |
| **Capsule endoscopy system** | Pillcam  SB3 | Pillcam  COLON2 | EndoCapsule  EC-S10 | MiroCam  MC1000-W | OMOM JS-ME-II | CapsoCam Plus |
| **Size (mm)** | 26 x 11 | 32 x 12 | 26 x 11 | 25 x 11 | 28 x 13 | 31 x 11 |
| **Cameras (n)** | 1 | 2 | 1 | 1 | 1 | 4 |
| **Viewing direction** | Longitudinal | Longitudinal | Longitudinal | Longitudinal | Longitudinal | Lateral |
| **Weight (g)** | 3.0 | 2.9 | 3.3 | 3.3 | 6.0 | 4.0 |
| **Minimum battery life (h)** | 11 | 10 | 12 | 12 | 9 | 15 |
| **Image sensor** | CMOS | CMOS | CMOS | CMOS | CMOS | CMOS |
| **Framerate (frames/s)** | 2-6 | 4-35 | 2 | 3 | 2 | 12-20 |
| **Field of view (o)** | 156 | 172 | 160 | 170 | 140 | 360 |
| **Image transmission** | Radiofrequency | Radiofrequency | Radiofrequency | Human body communication\*\* | Radiofrequency | None\*\*\* |

CMOS: Complementary metal oxide semiconductor

\* The image resolution of different capsule endoscopy systems were provided by the manufacturer. For OMOM JS-MW-II data are stated in the literature.[[88](#_ENREF_88)]

\*\* Data are transmitted to sensor electrodes on the skin using the human body as a conductor.

\*\*\* Data are stored in the capsule in an onboard flash memory. The patient retrieves the capsule and returns it to the medical staff for data download.

**Table 3** Studies comparing the sensitivity and specificity of capsule endoscopy for diagnosing small bowel CD with different gold standards.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Study design | Diagnostic lesions at CE | Gold standard | n | Sensitivity (%) | Specificity (%) |
| *Dubcenco, 2005 [*[*34*](#_ENREF_34)*]* | Prospective | Ulcerations | Biopsy from the terminal ileum | 39 | 90 | 100 |
| *Albert, 2005 [*[*29*](#_ENREF_29)*]* | Prospective | Ulcerations | Follow-up | 25 | 92 | 100 |
| *Solem, 2008 [*[*30*](#_ENREF_30)*]* | Prospective | Unknown | Consensus based on the results of CE, CT, SB radiography and IC | 27 | 83 | 53 |
| *Tukey, 2009 [*[*89*](#_ENREF_89)*]* | Retrospective analysis of CEs performed after a negative IC and SB radiography | Ulcerations | Follow-up | 102 | 77 | 89 |
| *Jensen, 2011 [*[*7*](#_ENREF_7)*]* | Prospective | Ulcerations | IC | 69 | 100 | 91 |

CE: Capsule endoscopy

CT: Computed tomography

IC: Ileocolonoscopy

SB: Small bowel

**Table 4** Validated indexes for determining the severity of Crohn’s disease in the small bowel with capsule endoscopy.

**A)**

|  |
| --- |
| *Lewis score* |
| Villous appearance *(for each small bowel tertile\*)*  Number: normal (0) or edematous (1)  Longitudinal extent\*\*: short segment (8), long segment (12) or whole tertile (20)  Descriptor: singe (1), patchy (14) or diffuse (17)  Ulcer *(for each small bowel tertile\*)*  Number: no ulcers (0), one ulcer (3), two to seven ulcers (5) or eight or more ulcers (10)  Longitudinal extent\*\*: short segment (5), long segment (10) or whole tertile (15)  Descriptor: < ¼ (9), ¼-½ (12) or > ½ (18) of the capsule picture occupied by the largest ulcer  Stenosis  Number: none (0), single (14) or multiple (20)  Ulcerated (24) or non-ulcerated (2)  Traversed (7) or not traversed (10) by the capsule  Total Lewis score = score of the worst affected tertile  (villous appearance × extent × descriptor + ulcer number × extent × size) + stenosis number × ulcerated × traversed |

*\*The small bowel is divided in to tertiles according to the transit time*

*\*\* Short segment: < 10% of the tertile; long segment: 11–50% of the tertile; whole segment: > 50% of the tertile*

**B)**

|  |
| --- |
| *Capsule Endoscopy Crohn's Disease Activity Index (CECDAI)* |
| A. Inflammation score  0 = None ; 1 = Mild to moderate edema/hyperemia/denudation ; 2 = Severe edema/hyperemia/denudation ; 3 = Bleeding, exudate, aphthae, erosion, small ulcer (< 0.5 cm) ; 4 = Moderate ulcer (0.5–2 cm), pseudopolyp ; 5 = Large ulcer (> 2 cm)  B. Extent of disease score  0 = None ; 1 = Focal disease (single segment) ; 2 = Patchy disease (multiple segments) ; 3 = Diffuse disease  C. Narrowing (stricture)  0 = None ; 1 = Single-passed ; 2 = Multiple-passed ; 3 = Obstruction  Total score = (A1 x B1 + C1) + (A2 x B2 + C2)\* |

*\*The small bowel is divided in to a proximal (1) and distal (2) segment according to the transit time*

**FIGURES**

**Figure 1** Crohn’s disease of the small bowel detected with capsule endoscopy: A) normal small bowel mucosa, B) aphthous ulceration, C) linear ulcers, and D) ulcerated stenosis

**Figure 2** The internationally recommended diagnostic algorithm in patients with A) suspected Crohn’s disease and B) symptomatic known Crohn’s disease [[8](#_ENREF_8), [26](#_ENREF_26)]